Proton beam therapy and iris neovascularisation in uveal melanoma

被引:16
|
作者
Boyd, S. R.
Gittos, A.
Richter, M.
Hungerford, J. L.
Errington, R. D.
Cree, I. A. [1 ]
机构
[1] Alexandra Hosp, Translat Oncol Res Ctr, Dept Histopathol, Michael Darmady Lab, Portsmouth PO6 3LY, Hants, England
[2] UCL, Dept Pathol, Inst Ophthalmol, London, England
[3] Univ Toronto, Dept Ophthalmol, St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[4] Univ Toronto, Vasc Biol Res Grp, St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[5] Moorfields Eye Hosp, London, England
[6] Univ Med Berlin, Ophthalm Clin, Berlin, Germany
[7] Clatterbridge Ctr Oncol, Wirral, Merseyside, England
关键词
iris; angiogenesis; glaucoma; melanoma; proton; irradiation;
D O I
10.1038/sj.eye.6702072
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Local treatment of uveal melanoma by radiotherapy involves the use of brachytherapy with radioactive plaques attached to the sclera, or proton irradiation. Both treatments induce growth arrest within the tumour and its slow involution over several years. Although ocular retention rates are excellent, regrowth of tumours due to resistance and neovascular glaucoma leads to enucleation of up to 10% of affected eyes. Proton irradiation involves part of the iris in most cases and we noticed that neovascularisation only occurred in the part of the iris that was not irradiated. We therefore conducted this study to determine the relationship between the development of iris neovascularisation and iris irradiation. Methods A total of 21 enucleation specimens from patients who had previously had proton irradiation were collected from the files of the Department of Pathology, Moorfields Eye Hospital during the 5-year period from 1994 to 1999. Sections of these eyes were assessed for VEGF-A, bFGF, and von Willebrand Factor (vWF) by immunohistochemistry. Ophthalmic notes and radiotherapy records were reviewed to assess the extent of iris irradiation. Results In all, 11 cases showed clinical evidence of iris neovascularisation and were selected for further study. Three of these eyes also showed clinical evidence of regrowth of the tumour. Histological evidence of iris neovascularization was noted in all 11 of the eyes examined, and was only present in the nonirradiated side of the iris in 8/11 eyes. NVI was present on both sides of the iris in three cases, but was less severe in the irradiated part. Expression of VEGF-A was at most weak within the tumour, but was present in the detached retina and in the epithelium of both ciliary body and iris. Some bFGF staining was noted around vessels in the iris stroma. Conclusions Our results suggest that irradiation leads to iris atrophy, and that atrophic, irradiated iris is resistant to the development of neovascularisation.
引用
收藏
页码:832 / 836
页数:5
相关论文
共 50 条
  • [21] When is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma?
    Gillam, Matthew
    Fenech, Glenn
    Chadwick, Oliver
    Nairn, Jonathan
    Chadha, Vikas
    Connolly, Julie
    Cram, Oliver
    Kincaid, Wilma
    Cauchi, Paul
    OCULAR ONCOLOGY AND PATHOLOGY, 2023, 9 (5-6) : 130 - 137
  • [23] Cataract development in patients treated with proton beam therapy for uveal melanoma
    Ira Seibel
    Dino Cordini
    Annette Hager
    Aline I. Riechardt
    Matus Rehak
    Alexander Böker
    Dirk Böhmer
    Jens Heufelder
    Antonia M. Joussen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 1625 - 1630
  • [24] POSTERIOR UVEAL MELANOMA IN YOUNG PATIENTS TREATED WITH PROTON BEAM THERAPY
    Vavvas, Demetrios
    Kim, Ivana
    Lane, Anne Marie
    Chaglassian, Alan
    Mukai, Shizuo
    Gragoudas, Evangelos
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (08): : 1267 - 1271
  • [25] Cataract development in patients treated with proton beam therapy for uveal melanoma
    Seibel, Ira
    Cordini, Dino
    Hager, Annette
    Riechardt, Aline I.
    Rehak, Matus
    Boeker, Alexander
    Boehmer, Dirk
    Heufelder, Jens
    Joussen, Antonia M.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (08) : 1625 - 1630
  • [26] Proton beam therapy in uveal melanoma patients from the Rotterdam Ocular Melanoma Studygroup
    van Poppelen, N. M.
    Wu, M.
    Yavuzyigitoglu, S.
    Bakker, P. A. C.
    Kroesen, M.
    van Rij, C.
    Slagter, C.
    Naus, N. C.
    Kilic, E.
    ACTA OPHTHALMOLOGICA, 2023, 101 : 37 - 37
  • [27] Proton beam radiotherapy of iris melanoma
    Damato, B
    Kacperek, A
    Chopra, M
    Sheen, MA
    Campbell, IR
    Errington, RD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (01): : 109 - 115
  • [28] Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR)
    Qureshi, S.
    Hussain, R.
    Kalirai, H.
    Heimann, H.
    Coupland, S.
    ACTA OPHTHALMOLOGICA, 2016, 94
  • [29] Radiological work-up for proton beam therapy of uveal melanoma patients
    Jaarsma-Coes, Myriam
    Marinkovic, Marina
    Ferreira, Teresa
    Vu, Khanh
    van Vught, Luc
    van Haren, Guido
    Rodrigues, Myra
    Klaver, Yvonne
    Verbist, Berit
    Luyten, Gregorius
    Rasch, Coen
    Beenakker, Jan-Willem
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [30] Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy
    Amir Mahdjoubi
    Marie Najean
    Stéphanie Lemaitre
    Sylvain Dureau
    Rémi Dendale
    Christine Levy
    Livia Lumbroso-Le Rouic
    Laurence Desjardins
    Nathalie Cassoux
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256 : 411 - 420